All about covaxin

All about covaxin

Hyderabad: Bharat Biotech has announced that the vaccine being developed by the company will soon enter human trials. The vaccine being developed by the Hyderabad company is India's first vaccine candidate to enter clinical trials. According to a report by ANI, the company developed the vaccine, Covaxin in collaboration with ICMR and the national institute to virology (NIV) by using a strain of  SARS-CoV-2 which was isolated at the NIV. The inactive virus was then used to create Covaxin in the company’s Bio Safety Level 3 (BSL-3) lab located in Genome Valley, Hyderabad

• The vaccine being developed by the University of Oxford in partnership with British-Swedish multinational pharmaceutical company, AstraZeneca is leading the path to COVID-19 vaccine candidate is the first to reach the final stages of clinical trials. The vaccine candidate ChAdOx1 nCoV-19 is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees. The vaccine has entered phase 2 and 3 of the trails and will also be conducting tests in Brazil and South Africa.
• Another vaccine that is leading the race is the one being developed US-based Biotech company Moderna which will begin Phase 3 trials from July. This is an RNA based vaccine and is being developed in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID).
• According to a report by Reuters, China National Biotec Group is ready to conduct the phase 3 trial of its vaccine in the United Arab Emirates (UAE). It is the first Chinese firm to begin the Phase 3 trial. The company has not disclosed the details of the vaccine or the trial yet.
• Germany based BioNTech and US-based Pfizer have also started Phase 1 and 2 trials of the BNT162 an RNA based vaccine. The company has said that they might be able to start manufacturing from October this year.